Beimei Pharma and Deva Holding A.Ş. reached an exclusive license and supply agreement in China for one product that have been approved for marketing in European

On December 2, 2020, Shenzhen Beimei Pharma Co., Ltd. (hereinafter referred to as "Beimei Pharma") and Deva Holding A.Ş. of Turkey (hereinafter referred to as "Deva") signed an exclusive and supply agreement in China for a liquid formulation (hereinafter referred to as "the Product") , Beimei Pharma is responsible for its registration and commercialization in Mainland China.

This product is a systemic antifungal drug, acting on invasive fungal infections, and is the unqiue drug indicated for the prevention of invasive fungal infections. The product has a broad antibacterial spectrum, with the advantage of precise efficacy, good tolerability and few adverse effects, and is unanimously recommended by domestic and international guidelines. Invasive fungal disease (IFD) is a major cause of morbidity and mortality in immunocompromised patients. Patients with hematologic malignancies, such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT), are at high risk of developing IFD. In addition to the above causes, children who have immune dysfunction, ICU stay, solid organ transplantation and newborns (low birth weight) are also the high-risk factors for IFD. In recent years, the incidence of IFD in children has been on the rise. Patients with risk factors for IFD can be pre-medicated with antifungal drugs to prevent the occurrence of IFD before clinical symptoms of infection appear.

This product is a child-specific dosage form and has been approved for marketing in Germany, the Netherlands and other European countries. In addition, clinical studies related to the expansion of indications and age groups have been conducted worldwide and will further expand the drug population and indications for more patients in the future. As a high-quality imported generic drug, the successful launch of this product in China in the future will be a better complement to the Chinese market, covering the Chinese market more extensively and meeting the different needs of patients.

As of 2019, the global annual sales of the drug molecule reached $780 million (RMB 5.4 billion). The sales of the drug molecule that have been marketed in China amounted to RMB 140 million and have been growingrapidly,with a promising market size. The successful launch of this product in China will well meet the clinical needs of pediatric patients.

About Deva Holding A.Ş.

Deva Holding A.Ş. (Deva) is a long-established Turkish pharmaceutical company that manufactures and markets pharmaceutical products covering therapeutic areas such as skin, respiratory, cardiovascular system and infections. Its products are distributed to Turkey, Switzerland, Germany, the Netherlands, the United Kingdom, Canada, New Zealand and Australia. DEVA has three production sites with a total area of 216,409 square meters and a production capacity of 578 million units of pharmaceutical products per year, and its facilities are approved by the Turkish Ministry of Health, the European Union and the US FDA.

About Beimei Pharma

Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.